Can we count your visit with Google Analytics? No ads, no profiles. Details
LLY
NYSEAnalystsBuy29+4%Health Care · Pharmaceuticals
Each weekday: the watchlist of pullbacks inside uptrends, every new ticker teardown, and the bubble shifts that move names like this one. Free. Education, not advice.
Free when you join: the $HOOD Teardown Dossier (Robinhood Markets), the full desk file we sell in the shop. One per new reader.
No spam. One email per day max, unsubscribe in one click. Pro ($49/mo) includes every dossier and report in the shop.
Structural read: incretin franchise (tirzepatide) is the single largest near-term revenue driver in pharma, with GLP-1 TAM estimates in the $100-150B range by early 2030s and LLY + $NVO splitting the duopoly. Capacity - not demand - has been the binding constraint; LLY has committed $50B+ cumulative capex across Indiana, North Carolina, and Europe to expand fill-finish and API.
Pipeline optionality from oral GLP-1 (orforglipron) and next-gen multi-agonists (retatrutide) extends the runway past tirzepatide LOE.
It reads our $LLY data (thesis, key levels, peers, a year of prices) and any chart screenshot you paste, then explains the setup in plain English. Free with an email login, 5 questions a day. Education only: it never tells you to buy or sell, and it can be wrong, so check the numbers.
Long-form analysis touching LLY
High-signal only
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.